Single Amino-acid Changes That Confer Constitutive Activation of MTOR Are Discovered in Human Cancer

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2010 Mar 2

PMID 20190810

Citations 118

Authors

T Sato

A Nakashima

L Guo

K Coffman

F Tamanoi

Affiliations

Soon will be listed here.

Abstract

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates a variety of cellular functions such as growth, proliferation and autophagy. In a variety of cancer cells, overactivation of mTOR has been reported. In addition, mTOR inhibitors, such as rapamycin and its derivatives, are being evaluated in clinical trials as anticancer drugs. However, no active mutants of mTOR have been identified in human cancer. Here, we report that two different point mutations, S2215Y and R2505P, identified in human cancer genome database confer constitutive activation of mTOR signaling even under nutrient starvation conditions. S2215Y was identified in large intestine adenocarcinoma whereas R2505P was identified in renal cell carcinoma. mTOR complex 1 prepared from cells expressing the mutant mTOR after nutrient starvation still retains the activity to phosphorylate 4E-BP1 in vitro. The cells expressing the mTOR mutant show increased percentage of S-phase cells and exhibit resistance to cell size decrease by amino-acid starvation. The activated mutants are still sensitive to rapamycin. However, they show increased resistance to 1-butanol. Our study points to the idea that mTOR activating mutations can be identified in a wide range of human cancer.

Citing Articles

Differential somatic coding variant landscapes between laser microdissected luminal epithelial cells from canine mammary invasive ductal solid carcinoma and comedocarcinoma.

Deckwirth V, Hundi S, Hytonen M, Hannula S, Ellonen P, Bjorkenheim P BMC Cancer. 2024; 24(1):1524.

PMID: 39696035 PMC: 11657561. DOI: 10.1186/s12885-024-13239-w.

The mTOR pathway controls phosphorylation of BRAF at T401.

Christen D, Lauinger M, Brunner M, Dengjel J, Brummer T Cell Commun Signal. 2024; 22(1):428.

PMID: 39223665 PMC: 11370054. DOI: 10.1186/s12964-024-01808-2.

Sex, tissue, and mitochondrial interactions modify the transcriptional response to rapamycin in Drosophila.

Raynes Y, Santiago J, Lemieux F, Darwin L, Rand D BMC Genomics. 2024; 25(1):766.

PMID: 39107687 PMC: 11304892. DOI: 10.1186/s12864-024-10647-x.

The mTORC2 signaling network: targets and cross-talks.

Ragupathi A, Kim C, Jacinto E Biochem J. 2024; 481(2):45-91.

PMID: 38270460 PMC: 10903481. DOI: 10.1042/BCJ20220325.

The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization.

Liu Y, Zhang M, Jang H, Nussinov R Chem Sci. 2024; 15(3):1003-1017.

PMID: 38239681 PMC: 10793652. DOI: 10.1039/d3sc04690g.

References

Kranenburg O . The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 2005; 1756(2):81-2. DOI: 10.1016/j.bbcan.2005.10.001. View

Karbowniczek M, Spittle C, Morrison T, Wu H, Henske E . mTOR is activated in the majority of malignant melanomas. J Invest Dermatol. 2007; 128(4):980-7. DOI: 10.1038/sj.jid.5701074. View

Molinolo A, Hewitt S, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses Garcia A . Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res. 2007; 13(17):4964-73. DOI: 10.1158/1078-0432.CCR-07-1041. View

Fang Y, Bachmann R, Flanigan A, Chen J . Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001; 294(5548):1942-5. DOI: 10.1126/science.1066015. View

Edinger A, Thompson C . An activated mTOR mutant supports growth factor-independent, nutrient-dependent cell survival. Oncogene. 2004; 23(33):5654-63. DOI: 10.1038/sj.onc.1207738. View

Guertin D, Sabatini D . Defining the role of mTOR in cancer. Cancer Cell. 2007; 12(1):9-22. DOI: 10.1016/j.ccr.2007.05.008. View

English D, Cui Y, Siddiqui R . Messenger functions of phosphatidic acid. Chem Phys Lipids. 1996; 80(1-2):117-32. DOI: 10.1016/0009-3084(96)02549-2. View

Wang X, Proud C . Nutrient control of TORC1, a cell-cycle regulator. Trends Cell Biol. 2009; 19(6):260-7. DOI: 10.1016/j.tcb.2009.03.005. View

Robb V, Karbowniczek M, Klein-Szanto A, Henske E . Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol. 2006; 177(1):346-52. DOI: 10.1016/j.juro.2006.08.076. View

10.

Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F . Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A. 2007; 104(9):3514-9. PMC: 1805553. DOI: 10.1073/pnas.0608510104. View

11.

Sabatini D . mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6(9):729-34. DOI: 10.1038/nrc1974. View

12.

Patel J, McLeod L, Vries R, Flynn A, Wang X, Proud C . Cellular stresses profoundly inhibit protein synthesis and modulate the states of phosphorylation of multiple translation factors. Eur J Biochem. 2002; 269(12):3076-85. DOI: 10.1046/j.1432-1033.2002.02992.x. View

13.

Inoki K, Corradetti M, Guan K . Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2004; 37(1):19-24. DOI: 10.1038/ng1494. View

14.

Chiang G, Abraham R . Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007; 13(10):433-42. DOI: 10.1016/j.molmed.2007.08.001. View

15.

Aressy B, Ducommun B . Cell cycle control by the CDC25 phosphatases. Anticancer Agents Med Chem. 2008; 8(8):818-24. DOI: 10.2174/187152008786847756. View

16.

Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster D . Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2008; 29(6):1411-20. PMC: 2648237. DOI: 10.1128/MCB.00782-08. View

17.

Ohne Y, Takahara T, Hatakeyama R, Matsuzaki T, Noda M, Mizushima N . Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem. 2008; 283(46):31861-70. DOI: 10.1074/jbc.M801546200. View

18.

Reiling J, Sabatini D . Stress and mTORture signaling. Oncogene. 2006; 25(48):6373-83. DOI: 10.1038/sj.onc.1209889. View

19.

Ray D, Kiyokawa H . CDC25A levels determine the balance of proliferation and checkpoint response. Cell Cycle. 2007; 6(24):3039-42. DOI: 10.4161/cc.6.24.5104. View

20.

Sancak Y, Thoreen C, Peterson T, Lindquist R, Kang S, Spooner E . PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007; 25(6):903-15. DOI: 10.1016/j.molcel.2007.03.003. View